M Ventures
Profile, fund size and portfolio
M Ventures is the corporate venture arm of Merck KGaA, Darmstadt, Germany (pharmaceuticals, life science and electronics). It was founded in 2009 and is based in Amsterdam, Netherlands. It invests from Series A to Series C+ in healthcare, life Science, electronics.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Series A to Series C+ |
| Sectors | Healthcare, Life Science, Electronics, Frontier Technology and |
| Geography | Europe, North America, Middle East and Africa |
| Offices | Amsterdam, Netherlands, Darmstadt, Germany |
Sources: S4 M Ventures news archive (2015 to 2026); S3 M Ventures portfolio (category and exit filters); S5 M Ventures contact (offices).
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Healthcare | 42 | 48.8% |
| Electronics | 21 | 24.4% |
| Frontier Technology and Sustainability | 12 | 14% |
| Life Science | 11 | 12.8% |
A company can carry more than one tag
Sources: S3 M Ventures portfolio (category and exit filters).
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | EUR 600M | Fund size | Stated by the firm or its parent | S1 |
| Companies backed | 100+ | companies | Stated by the firm | S1 |
| IPOs | 7 | IPOs | Stated by the firm | S3 |
| M&A exits | 12 | exits | Stated by the firm | S3 |
| Companies on the firm's portfolio page | 86 | companies | Counted from the firm's own list | S3 |
Sources: S1 M Ventures home; S3 M Ventures portfolio (category and exit filters).
Where it invests and who leads it
Geography
- Headquarters
- Amsterdam, Netherlands
- Offices
- Amsterdam, Netherlands
- Darmstadt, Germany
Investment regionsS4S3S5
- Europe
- North America
- Middle East and Africa
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Merck KGaA, Darmstadt, Germany | Single source | S1 |
| Parent industry | Pharmaceuticals, life science and electronics | Single source | S1 |
| Founded | 2009 | Single source | S1 |
| Headquarters | Amsterdam, Netherlands | Single source | S5 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S1 |
| Headline size | EUR 600M (Fund size) | Single source | S1 |
| Companies backed | 100+ | Single source | S1 |
| Exits | 19 total, 7 IPOs, 12 M&A | Single source | S3 |
| People on the team page | 23 | Single source | S2 |
| Stages | Series A, Series B, Series C+ (inferred from announced rounds) | Estimate | S4 |
Portfolio
The firm's portfolio page lists 86 companies: 67 active, 19 exited.S3
The firm also states 100+ companies backed. The page list and the stated total measure different things.S1
| Tag | Companies | Share |
|---|---|---|
| Active | 67 | 77.9% |
| Exited | 19 | 22.1% |
| Tag | Companies | Share |
|---|---|---|
| Healthcare | 42 | 48.8% |
| Electronics | 21 | 24.4% |
| Frontier Technology and Sustainability | 12 | 14% |
| Life Science | 11 | 12.8% |
Every company on the M Ventures list
86 companies, as listed on the firm's own website: 67 active, 19 exited.S3 Read the firm's list.
Active 67
- Abselion
- Actithera
- Altoida
- Anavo
- Anjuna Security
- Artios
- Asceneuron
- Astraveus
- beeOLED
- Biolinq
- CellFE
- ChEmpower
- Concerto Biosciences
- Corvic AI
- Cyllene Therapeutics
- DISCO Pharmaceuticals
- DNA SCRIPT
- Electroninks
- Enara Bio
- Ferroelectric Memory GmbH
- Formo
- FoRx Therapeutics
- Future Fertility
- Genopore
- IKAS
- Iktos
- ImmuneBridge
- iOmx Therapeutics
- iOnctura
- IonKraft
- Kivu Bioscience
- LabGenius
- Lightcast
- Lucidean
- Medisafe
- MemryX
- Metalenz
- Mosa Meat
- Multitude
- NanoSyrinx
- NeoLogic
- Neurable
- Nouscom
- NovoLINC
- NRG Therapeutics
- Nucleai
- Nucleome
- Outrun Therapeutics
- Pacific Light & Hologram
- PictorLabs
- Plexium
- Polaris Electro-Optics
- PxE
- Quintessent
- Remepy
- ReproNovo
- Rewind
- ribometrix
- SEEQC
- Storm Therapeutics
- SynSense
- Theolytics
- Thintronics
- TRIMTECH Therapeutics
- TwoStep Therapeutics
- UNISERS
- Wiliot
Exited 19
- Akili
- Ambrx
- Calypso Biotech
- Celestial AI
- EpiTherapeutics
- F-Star Therapeutics
- Forendo Pharma
- Galecto Biotech
- Immunitas
- Immunorizon
- Lumiode
- ObsEva
- Padlock Therapeutics
- Prexton Therapeutics
- Progyny
- Synaffix BV
- TIGNIS
- Translate Bio
- x.ilio Therapeutics
Fund vehicles
Recent rounds
History
Where sources disagree
Official pages
Read the firm's own pages for current information.
- Website www.m-ventures.com
- Portfolio www.m-ventures.com/portfolio
- LinkedIn company page www.linkedin.com/company/merck-ventures/
Sources
- S1M Ventures homeFirm
- S2M Ventures teamFirm
- S3M Ventures portfolio (category and exit filters)Firm
- S4M Ventures news archive (2015 to 2026)Firm
- S5M Ventures contact (offices)Firm
- S6M Ventures: Javier Rodriguez bioFirm
- S7M Ventures: Hakan Goker bioFirm
- S8M Ventures: Bauke Anninga bioFirm
- S9M Ventures: Christian Patze bioFirm
- S10M Ventures: Christian Uhrich bioFirm
- S13M Ventures: Merck KGaA expands M Ventures with a new EUR 600 million investment (Dec 2021)Firm
- S14M Ventures: Actithera raises USD 75.5M Series AFirm
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by M Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.